Surmodics, Inc. reiterated earnings guidance for the year 2022. For the year, the company expects revenue to range from $97 million to $101 million. Diluted GAAP EPS is expected to range from a loss per share of $2.05 to $1.55, which reflects increased investments to accelerate the Company's strategy.